Acute pain relief after Mantram meditation in children with neuroblastoma undergoing anti-GD2 monoclonal antibody therapy

Title

Acute pain relief after Mantram meditation in children with neuroblastoma undergoing anti-GD2 monoclonal antibody therapy

Creator

Ahmed M; Modak S; Sequeira S

Publisher

Journal Of Pediatric Hematology/oncology

Date

2014

Subject

adolescent; Child; Female; Humans; Male; retrospective studies; Pain; Neuroblastoma; Antineoplastic Agents; Preschool; Meditation; Antibodies; Gangliosides; Monoclonal

Description

Nonpharmacologic, mind-body interventions are used to reduce anxiety in pediatric patients. Anti-ganglioside GD2 monoclonal antibody (anti-GD2 MoAb 3F8) therapy is the standard of care for high-risk neuroblastoma and pain is its major side effect. We performed a retrospective analysis of children undergoing anti-GD2 MoAb 3F8 treatment who received guided meditation. Meditation involved concentrating on the repetition of rhythmic, melodic sounds purported to slow breathing and induce a relaxation response. A total of 71% patients completed a session at first (n=19) or second attempt (n=5). Patients received fewer analgesic doses to manage anti-GD2 MoAb 3F8-induced pain when participating in meditation (n=17, mean=-0.4 dose, P<0.01). Mantram meditation is a feasible outpatient intervention associated with reduced analgesic requirements.
2014-03

Rights

Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).

Type

Journal Article

Citation List Month

Backlog

Pages

152-155

Issue

2

Volume

36

Citation

Ahmed M; Modak S; Sequeira S, “Acute pain relief after Mantram meditation in children with neuroblastoma undergoing anti-GD2 monoclonal antibody therapy,” Pediatric Palliative Care Library, accessed November 27, 2021, https://pedpalascnetlibrary.omeka.net/items/show/14981.

Social Bookmarking